HALO
Price
$67.03
Change
+$0.15 (+0.22%)
Updated
Oct 17 closing price
Capitalization
7.84B
22 days until earnings call
XENE
Price
$41.63
Change
-$0.54 (-1.28%)
Updated
Oct 17 closing price
Capitalization
3.21B
17 days until earnings call
Interact to see
Advertisement

HALO vs XENE

Header iconHALO vs XENE Comparison
Open Charts HALO vs XENEBanner chart's image
Halozyme Therapeutics
Price$67.03
Change+$0.15 (+0.22%)
Volume$2.24M
Capitalization7.84B
Xenon Pharmaceuticals
Price$41.63
Change-$0.54 (-1.28%)
Volume$832.12K
Capitalization3.21B
HALO vs XENE Comparison Chart in %
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HALO vs. XENE commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (HALO: $67.03 vs. XENE: $41.63)
Brand notoriety: HALO and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 105% vs. XENE: 111%
Market capitalization -- HALO: $7.84B vs. XENE: $3.21B
HALO [@Biotechnology] is valued at $7.84B. XENE’s [@Biotechnology] market capitalization is $3.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 2 FA rating(s) are green whileXENE’s FA Score has 2 green FA rating(s).

  • HALO’s FA Score: 2 green, 3 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than HALO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • HALO’s TA Score: 5 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both HALO and XENE are a good buy in the short-term.

Price Growth

HALO (@Biotechnology) experienced а +4.57% price change this week, while XENE (@Biotechnology) price change was +5.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

HALO is expected to report earnings on Nov 10, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($7.84B) has a higher market cap than XENE($3.21B). HALO YTD gains are higher at: 40.201 vs. XENE (6.199). HALO has higher annual earnings (EBITDA): 792M vs. XENE (-315.5M). HALO has more cash in the bank: 548M vs. XENE (488M). XENE has less debt than HALO: XENE (8.72M) vs HALO (1.51B). HALO has higher revenues than XENE: HALO (1.18B) vs XENE (7.5M).
HALOXENEHALO / XENE
Capitalization7.84B3.21B244%
EBITDA792M-315.5M-251%
Gain YTD40.2016.199649%
P/E Ratio15.34N/A-
Revenue1.18B7.5M15,720%
Total Cash548M488M112%
Total Debt1.51B8.72M17,315%
FUNDAMENTALS RATINGS
HALO vs XENE: Fundamental Ratings
HALO
XENE
OUTLOOK RATING
1..100
6515
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
3333
SMR RATING
1..100
1197
PRICE GROWTH RATING
1..100
5143
P/E GROWTH RATING
1..100
726
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XENE's Valuation (73) in the Biotechnology industry is in the same range as HALO (77). This means that XENE’s stock grew similarly to HALO’s over the last 12 months.

XENE's Profit vs Risk Rating (33) in the Biotechnology industry is in the same range as HALO (33). This means that XENE’s stock grew similarly to HALO’s over the last 12 months.

HALO's SMR Rating (11) in the Biotechnology industry is significantly better than the same rating for XENE (97). This means that HALO’s stock grew significantly faster than XENE’s over the last 12 months.

XENE's Price Growth Rating (43) in the Biotechnology industry is in the same range as HALO (51). This means that XENE’s stock grew similarly to HALO’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for HALO (72). This means that XENE’s stock grew significantly faster than HALO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOXENE
RSI
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
63%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
66%
Bullish Trend 3 days ago
76%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
Bearish Trend 10 days ago
67%
Bearish Trend 13 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 3 days ago
77%
Aroon
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USPCX31.260.22
+0.71%
Union Street Partners Value C
CMEUX23.780.12
+0.51%
Six Circles Mgd Eq Port US Uncons
ICSCX28.740.08
+0.28%
William Blair Small Cap Value I
PICRX47.350.11
+0.23%
Putnam International Small Cap R
BDBPX26.96-0.16
-0.59%
iShares Russell 2000 Small-Cap Idx Inv P

HALO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
+0.22%
AXON - HALO
47%
Loosely correlated
+2.84%
XENE - HALO
44%
Loosely correlated
-1.28%
IRON - HALO
37%
Loosely correlated
+20.95%
TECH - HALO
37%
Loosely correlated
+0.42%
ARGX - HALO
35%
Loosely correlated
+0.76%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with NUVL. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-1.28%
NUVL - XENE
61%
Loosely correlated
+2.32%
IDYA - XENE
56%
Loosely correlated
+5.67%
NRIX - XENE
53%
Loosely correlated
-1.89%
DNLI - XENE
50%
Loosely correlated
-0.36%
CRNX - XENE
50%
Loosely correlated
-1.75%
More